Loading…
Wittman Pharma, Inc., a manufacturer of over-the-counter cough, cold, and allergy medications, violated Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals during an FDA inspection from February to March 2024. The company's quality control unit failed to ensure adequate oversight and released drug product batches without completing required testing, including approving finished products for shipment before microbial testing was performed and documented. Specifically, the firm shipped multiple units of a batch on July 19, 2023, but did not conduct microbial testing until August 10, 2023, and did not approve the finished product test specification until August 23, 2023—practices that violated both CGMP requirements and the company's own procedures. These manufacturing control failures rendered the drug products adulterated under the Federal Food, Drug, and Cosmetic Act.